More recently, other researchers, such as Zhang et al recently provided solid genetic and biochemical evidence that pharmacological targeting of KDM3A is an effective strategy to counteract left ventricular hypertrophy.18 However, its potential role in AMI has not been explicitly delineated. The gene discussed is KDM3A; the disease is left ventricular hypertrophy.